<unk>  is a combination of two nucleoside analog reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor that is FDA approved for the treatment of HIV-1 infection. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include headache, dizziness, drowsiness, hyperlipoproteinemia, insomnia, abnormal dreams, skin rash, diarrhea, vomiting, nausea, abdominal pain, gastroenteritis, infection, weakness, otitis media, cough, rhinitis, and fever.
Emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate
Efavirenz, emtricitabine and tenofovir disoproxil fumarate
Emtricitabine and tenofovir alafenamide fumarate
Emtricitabine and tenofovir disoproxil fumarate
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Efavirenz, Emtricitabine, and Tenofovir disoproxil fumarate
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate
Bictegravir / emtricitabine / tenofovir alafenamide